Human Heart Generates Complement Proteins That Are Upregulated and Activated After Myocardial Infarction

From the Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver.

Correspondence to Dr Patrick L. McGeer, Kinsmen Laboratory of Neurological Research, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada. E-mail mcgeerpl{at}unixg.ubc.ca

Abstract

Abstract—In human heart, we detected mRNAs and proteins for C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9 with the use of reverse transcriptase–polymerase chain reaction, Western blotting, and immunohistochemical techniques. We found an upregulation of both mRNAs and proteins in areas of recent and old myocardial infarctions. In both situations, the classical complement pathway was activated, with C4d, C3d, and the membrane attack complex (C5b-9) being deposited on damaged cardiac myocytes. These activated complement components were also identified on Western blots of infarcted tissue. Complement mRNAs in infarcted heart tissue were higher than those in liver, and liver complement mRNAs were not upregulated in cases with infarcted hearts. Our results establish that (1) complement proteins are endogenously produced by human heart; (2) the classical complement pathway is fully activated after myocardial infarction; (3) complement activation is directly involved in myocardial damage after ischemic insults; and (4) damage from complement activation may be chronically sustained. These data suggest that inhibition of the complement system should be effective in treating myocardial infarction.

Key Words: complement gene expression • classical pathway • postmortem delay • immunohistochemistry • Western blotting • liver complement

There have been many reports on association of complement proteins with myocardial damage. These include human myocardial infarcts,^{1 2 3 4 5 6 7 8} as well as damaged hearts in animal models of ischemia.^{8 9 10 11 12 13 14 15 16} Activation of both the classical and alternative complement pathways has been reported.^{17 18} Evidence that such activation is not an epiphenomenon, but contributes to tissue injury, comes directly from postmortem examination of human heart in which the membrane attack complex (MAC, C5b-9) has been identified on damaged muscle fibers.^{4 7 19} It comes indirectly from animal models in which ischemic myocardial damage is ameliorated by interference with complement activation. Intervention by administration of C1 esterase inhibitor,^{18 20 21} antibodies to C5a,²² and the soluble form of CR-1^{23 24} has reduced myocardial damage. The particular role of the MAC (C5b-9) comes from evidence that rabbits deficient in the complement protein C6 have a reduced infarct size in cardiac ischemia-reperfusion models compared with C6-sufficient rabbits.²⁵

It has traditionally been assumed that liver is the source of complement proteins that participate in these events. But we have recently shown that complement proteins are produced in several organs of the body, including brain and heart. We²⁶ have also shown that production of C3 and C9 mRNAs and their protein products is sharply upregulated in isolated rabbit heart after reperfusion injury, and that the production by heart in this circumstance substantially exceeds that of normal liver. In brain, we^{27 28} have shown that all proteins of the classical complement pathway are produced by neurons, and that this production is upregulated in Alzheimer disease, a condition characterized by a chronic neuroinflammatory state.²⁹

In the present study, we report that human heart expresses the mRNAs and proteins for all of the components of the classical complement pathway. We also report that this production is upregulated in areas of myocardial infarct, and that the classical complement pathway is fully activated on injured myocardial tissue. Most importantly, we report that continuing activation and damage occur in previous myocardial infarcts.

Materials and Methods

Cases Studied
Heart tissues from 12 autopsied subjects were used in the present study. Details of the cases are provided in Table 1. Subjects ranged in age from 25 to 94 years, with postmortem delays varying from 17 to 132 hours. Five of the subjects had heart disease as described below.

Case 1 was a 94-year-old man known to have ischemic heart disease and chronic renal failure. The patient suffered a myocardial infarct 2 months before death. Five days before death, he was admitted to hospital after a seizure. He was discharged after 3 days but readmitted to another hospital. At this time, elevated cardiac enzymes and ECG changes were noted. He died 2 days later. On autopsy, the heart was enlarged, with atherosclerotic occlusions in the right coronary artery, the left anterior descending artery, and the left circumflex artery. Areas of recent and old infarcts were clearly visible. Tissue was taken for analysis from a healthy, well-perfused area, a sclerotic area indicative of a previous infarct, and a mottled area characteristic of a recent infarct. In this case, and subsequent cases, the heart samples were thoroughly washed to remove all residual blood except that retained within capillaries.

Case 2 was a 78-year-old man with previous severe angina, admitted for a quadruple coronary bypass operation. The patient suffered an episode of cardiac arrest in the operating room. He deteriorated and died 3 days later. On autopsy, an extensive, recent myocardial infarction was seen to be superimposed on the background of an old myocardial infarction. An area of the damaged myocardium near the apex was taken for analysis.

Case 3 was a 78-year-old man with a known previous posterior myocardial infarct, who suddenly lost consciousness and died of cardiac arrest en route to the hospital. On autopsy, the heart was moderately enlarged, with significant stenosis of the left anterior descending and distal right coronary arteries. Posteriorly, there was an area of pallor and softening. Areas taken for analysis included the area of old infarction and a normal-appearing, well-perfused area.

Case 4 was a 71-year-old man admitted with a diagnosis of cardiovascular abnormality. Creatine kinase MB was 2.5 and creatine kinase 96, both within the normal hospital limits of 0 to 5 and 35 to 250, respectively. The patient deteriorated and died in hospital. A mottled area was taken for analysis. Microscopically, there was evidence of an acute myocardial infarct estimated to be 3 to 7 days old.

Case 5 was a 53-year-old woman who died in hospital after a subarachnoid hemorrhage. She was a diabetic with a history of angina and obstructive pulmonary disease. She had a myocardial infarct 3 years before death and a right lung transplant 2 months before death. On postmortem examination, the heart showed subendocardial fibrosis consistent with a previous myocardial infarct. A normal-appearing area and a damaged area were taken for analysis.

Cases 6 to 12 died from various causes as shown in Table 1. None of these 7 cases had any history of heart disease, and cardiac complications were not deemed to be a factor contributing to their deaths. On inspection, no gross abnormalities were detected in the heart tissue, and samples were taken from the left ventricle for analysis. Liver samples were also taken from cases 2 through 12.

RNA Extraction
Total RNA from approximately 500 mg of each tissue sample was extracted by the acid guanidinium thiocyanate-phenol-chloroform method.³⁰ The extracted RNA was quantified by scanning spectrophotometry. The Å260/280 ratio of all preparations was greater than 1.8. To avoid contamination of the mRNA with genomic DNA, all samples were treated with 10 U of RNase-free DNase (Pharmacia) for 60 minutes at 37°C in 25 µL of 1x reverse-transcriptase buffer ([in mmol/L] Tris-HCl 50, KCl 75, and MgCl₂ 3) containing 40 U of RNase inhibitor (Pharmacia) and 1 mmol/L dithiothreitol, followed by an incubation at 85°C for 5 minutes to inactivate the enzyme. To verify the absence of genomic DNA contamination of mRNA, an aliquot (200 ng) of each sample was subjected to polymerase chain reaction amplification without the reverse-transcriptase step.

Specific Complement Primers and Preparation of Reverse Transcriptase–Polymerase Chain Reaction (RT-PCR) Products
The DNA sequences of the genes of interest were obtained from the GenBank database. The specific PCR primers were designed on the basis of published human cDNA sequences. For all but C1r, genomic DNA data were also available. Primers were therefore chosen to span intron sequences, reducing the possibility of genomic DNA contamination of the RT-PCR products. Cyclophilin was selected as the reference standard, because it is expressed in virtually all types of tissues and has been highly conserved during mammalian evolution.^{31 32} The primer sequences are listed in Table 2.

For semiquantitative RT-PCR amplification, single-strand cDNA synthesis was first performed on 5 µg of total RNA. The reaction mixture consisted of the RNA sample, 25 µL of 1x reverse-transcriptase buffer containing 1 µg random hexamer primers (pDN6, Pharmacia), 1 mmol/L deoxynucleotides (Gibco BRL), 5 mmol/L dithiothreitol, 40 U of RNase inhibitor (Pharmacia), and 500 U of reverse transcriptase (Superscript TMII RT, Gibco BRL). Duplicate assays were carried out at 42°C for 90 minutes, followed by heat inactivation of the enzyme (65°C for 10 minutes).

The resultant cDNA (1 µL), covered with 50 µL of mineral oil, was amplified in a 50-µL reaction buffer containing 67 mmol/L Tris-HCl (pH 8.8), 16.6 mmol/L ammonium sulfate, 10 mmol/L 2-mercaptoethanol, 200 µmol/L dNTPs, 2 mmol/L MgCl₂, 40 pmol of each specific oligonucleotide primer, and 2.5 U of Taq DNA polymerase (Gibco BRL). The thermal profile, used on a Fisher Scientific programmable thermal controller, consisted of a denaturation step of 94°C for 1 minute, an annealing step of 55°C for 30 seconds, and an extension step of 72°C for 1 minute. The extension step in the first cycle was for 3 minutes at 72°C. All samples were initially denatured for a total of 5 minutes (94°C).

In preliminary studies, we found that the amount of PCR product increased exponentially from 20 cycles to 29 cycles for cyclophilin and from 25 cycles to 37 cycles for complement products. A plateau phase was reached after 29 and 37 cycles, respectively.³³ Accordingly, each cDNA sample was treated by the PCR procedure, with the cyclophilin product being amplified for 27 cycles and the complement products for 35 cycles. Each PCR product was electrophoresed through a 6% polyacrylamide gel, and the product was visualized by incubation for 10 minutes in a solution containing 10 ng/mL of ethidium bromide. Resulting gel bands were imaged using a GDS 6700 image analyzer (Ultra Violet Products). The relative intensities of the bands, expressed as optical density units, were quantitatively analyzed using NIH image software 1.61. Each complement mRNA analysis was made in parallel with a cyclophilin mRNA analysis to provide an internal standard. Values were analyzed relative to cyclophilin. Cyclophilin values were almost constant from sample to sample. Most were within 1% of each other, with the range less than 4%. Polaroid photographs of the gels were taken.

Restriction Digest Analysis
The PCR products were purified by the ethanol precipitation procedure. Unique restriction sites and restriction enzymes were selected using the DNA strider computer program. The restriction enzyme used for each PCR product is shown in Table 2. Each restriction digestion reaction was carried out for 2 hours at 37°C. The digested PCR products were analyzed by electrophoresis on a 6% nondenaturing polyacrylamide gel. In each case, the correct number of products was detected of the expected size (Table 2).

Western blots were performed on extracts of the soluble fraction of homogenates of normal and infarcted human heart tissue and compared with normal human serum and serum activated by aggregated IgG. Heart tissue samples were homogenized in 5x vol/wt extraction buffer (0.02 mol/L Tris-HCl, pH 7.5) containing the protease inhibitors PMSF (100 µg/mL) and aprotinin (10 µg/mL) and 1 mmol/L EDTA. Homogenates were centrifuged at 18 000g at 4°C for 30 minutes. The protein content of the supernatants was determined according to the Lowry method.³⁴ The samples were then diluted in SDS sample buffer (60 mmol/L Tris [pH 6.8]; 2.5% SDS, 5% ß-mercaptoethanol) to a final protein content of 1 mg/mL and were boiled for 3 minutes. Samples containing 20 µg of protein were loaded onto 7.5% acrylamide minigels.

Normal human serum taken from a 44-year-old male volunteer was diluted 1:20 in veronal buffer. A 2-mL aliquot of the diluted serum was mixed with 50 µL of a solution of 2 µg/mL heat-aggregated human IgG (Sigma). The mixture was incubated at 37°C for 1 hour. Aliquots of the normal and IgG-activated serum were then diluted in 2 volumes of SDS buffer and boiled for 3 minutes. Samples containing 20 µg of protein were loaded onto 7.5% acrylamide minigels. High-range prestained standards (Life Technologies) were used as molecular weight markers. After 45 minutes of electrophoresis (200 V), the proteins were transferred onto nitrocellulose membranes (Immobilon P, Millipore Corp) at 7 V for 45 minutes with use of a semidry blotter.

Because of the high molecular weight of the MAC, modifications of the electrophoresis and protein transfer steps were required. A 3% polyacrylamide gel was used, and separation was carried out for 11 hours at 25 V in a cold room with the apparatus surrounded by ice. The transfer to membranes was then carried out at 50 V for 11 hours in the cold.

Membranes were blocked in 5% low-fat milk for 2 hours. The immunoblots were then treated for 2 hours at room temperature with a primary anti-complement antibody, followed by treatment for 1 hour with an appropriate secondary antibody labeled with horseradish peroxidase. The primary antibodies were the same as those used for immunohistochemistry as described below. The appropriate secondary antibodies used were anti-goat HRP-conjugated IgG, anti-rabbit HRP-conjugated IgG, and anti-mouse HRP-conjugated IgG. All were from Sigma and were used at a 1:5000 dilution. Immunoreactivity was visualized by incubation with Supersignal CL-HRP chemiluminescent substrate (Pierce Chemical Co). After draining, the membranes were covered in clear plastic wrapping and exposed to x-ray film (Hyper film ECL, Amersham Life Science) for 0.3 to 2 minutes, depending on the strength of the signal.

Statistical Analysis
Data are expressed as mean±SE. Significance of the differences between the data for normal and infarcted tissue was assessed initially by 2-way ANOVA (pathology and mRNA type as the main factors) for global differences and then for differences in the individual mRNAs, by 1-way ANOVAs, followed by 2-tailed t tests with the use of Holm's stepdown procedure for multiple comparisons.³⁵ Analysis was done using the Macintosh StatView 512+ (Brain Power Inc). A value of P<0.05 was taken as indicating a significant difference.

Immunohistochemistry
Myocardial tissue samples for immunohistochemical and histochemical analysis were fixed for 2 to 3 days in 4% paraformaldehyde and were then transferred to a 15% phosphate buffered sucrose solution (pH 7.6). Immunohistochemistry was performed as previously reported.²⁸ Briefly, 30-µm sections were cut on a freezing microtome. To reduce endogenous peroxidase activity, free-floating sections were treated for 30 minutes with 0.3% H₂O₂ solution in 0.01 mol/L PBS (pH 7.4) containing 0.3% Triton X-100. The sections were incubated overnight at room temperature with primary antibodies. The sections were then washed and treated with appropriate biotinylated secondary antibodies for 2 hours at room temperature, followed by incubation in avidin-biotinylated horseradish peroxidase complex (ABC Elite, Vector Laboratory) for 1 hour at room temperature.

The primary antibodies and the dilutions used were as follows (where 2 figures for dilution are given, the first was used in immunohistochemistry and the second in Western blotting): goat anti-C1q (Quidel, 1:50 000, 1:5000); sheep anti-C1r (Binding Site, 1:5000); goat anti-C1r (ICN Biochemicals, 1:500, 1:10 000); goat anti-C1s (Quidel, 1:10 000, 1:2500); goat anti-C2 (Quidel, 1:10 000, 1:2000); goat anti-C3 (Calbiochem, 1:100 000, 1:10 000); goat anti-C4 (Chemicon, 1:100 000, 1:10 000); goat-antiC5 (Quidel, 1:50 000, 1:3000; goat anti-C6 (Calbiochem, 1:50 000, 1:2000); goat anti-C7 (Quidel, 1:10 000, 1:3000); goat anti-C8 (Calbiochem, 1:50 000, 1:5000); goat anti-C9 (Quidel, 1:50 000, 1:5000); rabbit anti-C3d (Quidel, 1:100 000, 1:5000); mouse anti-C4d (Quidel, 1:10 000, 1:3000); mouse anti-neoC4d (Quidel, 1:5000); mouse anti-sC5b-9 (Quidel, 1:1000); mouse anti-C5b-9 (DAKO, 1:1000, 1:1000); and rabbit anti-neosC5b-9 (Advanced Research Technologies, 1:2000). The secondary antibodies used were anti-goat biotin-conjugated IgG, anti-rabbit biotin-conjugated IgG, and anti-mouse biotin-conjugated IgG. All 3 were from Vector and were used at 1:1000 dilution. The detection kit used was the Vectastain ABC HRP Elite (Vector, 1:2000). Peroxidase labeling was visualized by incubation of the sections in 0.01% 3,3'-diaminobenzidine (Sigma) containing 0.6% nickel ammonium sulfate and 0.00015% H₂O₂ in 0.05 mol/L Tris-HCl buffer (pH 7.6). When a dark purple color developed, sections were washed, mounted on glass slides, and coverslipped with a gelatin solution in distilled water. Controls were performed by omitting the primary antibody.

For histochemical detection of collagen, the Gomori trichrome method was used.³⁶ Slide-mounted sections were washed in water, rinsed in 1% acetic acid, stained in Gomori's trichrome solution (containing Chromotrope 2R 0.6 g, Fast green FCF 0.3 g, phosphotungstic acid 0.6 g, and glacial acetic acid 1 mL per 100 mL of distilled water) for 2 to 3 minutes. After staining, the sections were washed in 1% acetic acid, dehydrated, cleared in xylene and coverslipped in Entellan (Merck kGaA).

Results

The postmortem delay for heart tissue used in the present study varied from 6 to 132 hours. To determine whether postmortem delay significantly influenced the results, multiple tests were done to determine the quality of total RNA extracted and of the RT-PCR products obtained from each sample. Gels were run on every RNA extract, and the bands for ribosomal RNA and transfer RNA were examined. These RNA species are highly sensitive to enzymatic degradation. There was little smearing of bands and little loss of intensity associated with the longer postmortem intervals, either of which would have been indicative of postmortem degradation.

To test directly the postmortem stability of total RNA and the mRNAs being studied, the heart of case 9 was sampled at 24 hours and the remainder stored at 4°C. At 144 hours postmortem, an adjacent sample was then taken, and the quality of total RNA extracted from the 2 samples was compared. Results are illustrated in Figure 1. The 28S and 18S ribosomal bands and the transfer RNA band appeared highly similar when run on the same gel (Figure 1A). Gels were also run of the RT-PCR products. Only very minor declines were observed for cyclophilin mRNA and C4 and C3 mRNAs (Figure 1B). These data indicate that, for the time interval involved, degradation of RNA was not a major factor in the results obtained.

View larger version (26K): [in this window] [in a new window]   Figure 1. Postmortem stability of RNA. A, Polaroid of formaldehyde denatured gel of total RNA from 2 samples of case 9 heart. Lane 1, 24-hour extract. Lane 2, 144-hour extract. Note the comparable integrity of bands in both lanes. B, Cyclophilin (Cyc), C3, and C4 mRNA levels by RT-PCR from the total RNA extracts of 24 and 144 hours. Cyclophilin units are 100x greater than C3 and C4. Notice the relatively small decrease in RT-PCR levels at 144 hours postmortem compared with 24 hours postmortem. For details, see Materials and Methods.

Detection of mRNAs
RT-PCR products for each of the complement mRNAs were identified in multiple samples from human hearts and liver. Figure 2 illustrates such identification in an electrophoretic gel. The RT-PCR products were of the predicted size. Each product was purified and subjected to digestion with a specific endonuclease (Table 2). The fragments were purified and separated by electrophoresis. In all cases, the endonuclease digestion gave the expected number of fragments, and they were of the predicted size, validating the identity of the RT-PCR products (Table 2).

View larger version (41K): [in this window] [in a new window]   Figure 2. Representative Polaroid photomicrograph showing gel electrophoresis of the RT-PCR products of infarcted heart extract of case 1. Size markers are in lane M with sizes given in base pairs. DNA products from PCR were resolved on a 6% polyacrylamide gel and visualized by ethidium bromide staining.

The quantitative levels of the RT-PCR complement products in heart varied according to the pathology. Cyclophilin mRNAs in heart were independent of cardiac pathology and independent of postmortem delay. Values for the RT-PCR products, in units relative to cyclophilin, are given in Table 1 for each complement mRNA in each heart sample. Analysis by 2-way ANOVA gave a P<0.0001 for the difference in complement mRNAs between normal tissue and recently infarcted tissue, as well as between normal tissue and old infarcted tissue. By contrast, a nonsignificant P value of 0.38 was obtained between recently infarcted tissue and old infarcted tissue. Results of the statistical tests for the effect of pathology on individual mRNAs are indicated in Table 3.

The quantitative levels of the RT-PCR complement products in liver did not vary with pathology or postmortem delay. Cyclophilin mRNA from liver was also independent of both postmortem delay and cardiac pathology. All of the complement mRNAs were easily detectable in all samples of infarcted heart tissue, whether recent or old (Table 1). In contrast, complement mRNAs in heart were low or undetectable in samples taken from subjects who died without a history of cardiac problems and with no gross abnormality visible in the postmortem heart (cases 6 to 12). C4 and C3 mRNAs were expressed at the highest levels in normal heart and liver, consistent with the relatively high levels of their translation products in normal serum.

Table 3 summarizes the relative levels of complement and cyclophilin mRNAs for normal, old myocardial infarcts, recent myocardial infarcts, and for samples from liver. The table shows that dramatic and highly significant increases in the mRNAs for almost all complement components occurred in old or recently infarcted heart tissue compared with normal heart tissue. The increases in infarcted tissue ranged from >20-fold for C1q to 1.2-fold for C3. Most increases were in the 3- to 5-fold range. These increased levels were higher than those typically found in liver. In contrast to heart, liver complement mRNAs were not elevated when the heart was infarcted. Cyclophilin levels in heart and liver were remarkably constant from sample to sample.

Figure 3 shows relative levels of complement and cyclophilin mRNAs in a normal area, a previously infarcted area, and a recently infarcted area of the heart of case 1. Large increases in complement mRNAs occurred in the damaged areas of heart compared with the undamaged areas, but there was no change in cyclophilin level. The data from this single heart were similar to the averages for all cases, as shown in Table 3.

View larger version (25K): [in this window] [in a new window]   Figure 3. Graph showing relative levels of complement mRNAs and cyclophilin mRNA in normal, old infarct, and recent infarct samples of case 1 heart. Optical density units represent readings of ethidium bromide gel band intensity as determined on a GDS 6700 image analyzer with quantitative analysis and use of NIH image software 1.61. Note that cyclophilin levels are constant, whereas there are sharp increases over normal in complement mRNAs in the infarcted areas. For details, see Materials and Methods.

Immunoblots
The results of Western blot experiments are shown in Figure 4. Lanes 1 and 2 are extracts from the recently infarcted sample and the normal sample of case 1. Lane 3 is from the normal serum sample, whereas lane 4 is from the same sample but after the complement system had been activated by aggregated human IgG. Bands were detected for all of the complement proteins from infarcted tissue (lane 1), with bands comigrating with those from normal serum (lane 3) and IgG-activated serum (lane 4). From the normal heart tissue extract, only bands for C3 and C4 and their degradation products were clearly visible (lane 2). Bands corresponding to full-length proteins were recognized by antibodies to C1r,³⁷ C1s,³⁷ C2,³⁷ C6,³⁸ C7,³⁸ and C9.³⁷ The antibody to C1q recognized a strong band at about 35 kDa, corresponding to the molecular weight of the chain.³⁹ The C3 antibody recognized strong bands at approximately 115 and 75 kDa, corresponding to the and ß chains, respectively.⁴⁰ An additional band at 35 kDa, corresponding to C3d,⁴¹ was weakly recognized in the infarcted heart extract and in the IgG-activated serum, indicating that the polyclonal antibody was recognizing an epitope in the C3d region. The C3d antibody strongly recognized this 35-kDa band. The C4 antibody detected a prominent band corresponding to the ß chain.⁴² The C4d antibody recognized a strong band in infarcted tissue and IgG-activated serum close to the 48-kDa value reported for C4d.⁴³ The C5 antibody detected a band corresponding to the reported value for the ß chain,⁴⁴ whereas the C8 antibody identified a band corresponding to the chain.⁴⁵ The antibody for C5b-9 (MAC) identified a strong band in the infarcted heart and complement-activated serum of a very high molecular weight, extrapolated to about 800 kDa, which is the reported molecular weight for the MAC.⁴⁶ The presence of C3d and C4d indicates that, in infarcted tissue as well as in IgG-activated serum, the complement cascade has been activated past the opsonization phase, with the presence of the MAC establishing full activation of the pathway by assembly of the terminal components into the final product.

View larger version (39K): [in this window] [in a new window]   Figure 4. Western blots from heart tissue and serum demonstrating the presence of complement proteins and their activation products. Lane 1, sample from an infarcted heart area of case 1. Lane 2, Sample from a normal heart area of case 1. Lane 3, Serum from a 44-year-old healthy man. Lane 4, Same serum as in lane 3 after activation of the complement system by aggregated IgG. Positions of molecular weight markers are shown by the arrows on the right; the estimated molecular weights of the main bands detected are shown by arrows on the left. Note that strong bands for all the complement proteins are visible in the infarcted heart sample, as well as the normal and complement-activated serum samples. The only strong band in the normal heart sample was for C3, with weak bands for C3d, C4, C4d, and C9 being detected. Note that the activated complement fragments C3d, C4d, and C5b-9 are strongly detected only in the infarcted heart and complement-activated serum sample. For details, see Materials and Methods.

Immunocytochemistry
Each of the antibodies clearly stained cardiomyocytes in infarcted tissue (Figure 5). Such staining was in contrast to that of adjacent normal cardiomyocytes. These results were consistent with those of Western blots (compare lane 1 versus lane 2 in Figure 5) in which strong positive bands were detected in extracts of infarcted tissue for all complement proteins. C3 showed the weakest contrast immunohistochemically between normal and infarcted cardiomyocytes, consistent with the relatively small upregulation in the mRNA (Table 3) and protein (Figure 4) in damaged myocardium. Thus, diffuse C3 immunostaining of normal cardiomyocytes may have reduced the contrast, with damaged cardiomyocytes visible with immunostaining for other complement proteins.

View larger version (85K): [in this window] [in a new window]   Figure 5. Immunohistochemical staining of infarcted heart by antibodies to complement proteins. The dark areas in each photomicrograph show damaged cardiomyocytes that are immunopositive. For details, see Materials and Methods. Bar in C9=200 µm and applies to all panels.

Figure 6 shows a much more dramatic increase between damaged and normal myocardium when immunohistochemistry was carried out using antibodies specific for complement activation. This is illustrated in serial sections taken from an acute infarct in case 2 and a chronic infarct in case 1. Gomori staining shows that the area examined from case 2 contains no collagenous scar tissue and therefore represents an acute infarct (Figure 6A). The area of damage is clearly outlined by immunostaining for C4d, C3d, and C5b-9 in Figure 6B, 6C, and 6D, respectively. To verify that full activation of the classical complement pathway had taken place, 2 antibodies against C4d and 3 antibodies against C5b-9 were tested. The 2 antibodies for C4d and the 3 antibodies for C5b-9 gave equivalent immunostaining.

View larger version (140K): [in this window] [in a new window]   Figure 6. Immunostaining of human myocardial infarcted tissue with antibodies specific for complement activation. A through D, Serial sections of a recently infarcted area of case 2. E through G, Serial sections of an old infarct of case 1. In each series, the same vessels are marked by stars (*). For details, see Materials and Methods. A and E, Gomori stain. B and F, anti-C4d. C and G, anti-C3d. D and H, anti–C5b-9. A, Gomori staining of the acute infarct shows dark cardiomyocytes (deep red in the original) throughout the field. B, Immunostaining for C4d shows dark cardiomyocytes interspersed with light areas composed of nonstaining undamaged cardiomyocytes. C, Immunostaining for C3d shows the same distribution of positively staining damaged cardiomyocytes as in panel B, except that the contrast is significantly less. D, Immunostaining for C5b-9 also shows the same distribution of positively staining damaged cardiomyocytes as in panels B and C. E, Gomori staining of the old infarct shows dark cardiomyocytes (deep red in the original) interspersed in lightly stained (pale green in the original) collagen scar tissue. F, Immunostaining for C4d shows heavy deposition on damaged but surviving cardiomyocytes. G, Immunostaining for C3d shows a similar distribution. Note the higher contrast with the unstained surround compared with panel C. H, Immunostaining for C5b-9 shows a similar distribution to C4d and C3d. Bar in D=200 µm and applies to panels A through D. Bar in H=100 µm and applies to panels E through H.

Figure 6E through 6H shows a previously infarcted area of case 1. The Gomori stain indicates surviving cardiomyocytes intermingled with extensive collagen deposits from old scarring (Figure 6E). Staining of serial sections showed intensive staining for C3d, C4d, and C5b-9 (Figure 6F through 6H), indicating activation of the full classical complement pathway in these cardiomyocytes. In this case, the intensity of C3d staining relative to the surrounding tissue was much stronger than for the acute infarct (compare Figure 6G with 6C), indicating a lack of C3 production in the contiguous collagenous areas.

Discussion

Postmortem stability is always a factor to consider in studies of human autopsy material. In this investigation, we examined tissues with postmortem delays varying from 17 to 144 hours. We found remarkably little difference in the quality of the total RNA extracted or in the levels of cyclophilin and C3 and C4 mRNAs detected by RT-PCR (see Figure 1). Moreover, the liver cyclophilin and complement mRNA levels did not vary with postmortem delay. These results illustrate that tissues that are kept in the cold, as is the case in most autopsy rooms, may have less postmortem deterioration than is commonly believed. Postmortem delay did not appear to be a factor in the results reported in the present study.

The present study demonstrates that in human heart tissue, all of the mRNAs for complement proteins are expressed, and in areas damaged by infarction, they are strongly upregulated (Tables 1 and 3). The complement mRNA levels in damaged heart exceed those of liver. Because liver mRNA levels are not increased in cases with cardiac damage, it is suggested that heart itself, and not liver, is the source of the complement proteins found in damaged tissue.

The source of tissue complement proteins has traditionally been assumed to be liver, with serum acting as the delivery vehicle. Previously, we²⁶ showed that isolated rabbit heart, perfused only with oxygenated buffer, was capable of synthesizing C3 and C9 mRNAs and their protein products. In this serum-free milieu, there was a 4.72-fold increase in C3 mRNA and a 19.5-fold increase in C9 mRNA after only 0.5 hours of ischemia followed by 1 hour of reperfusion. This indicates that increases in heart complement mRNAs can be induced rapidly. In hearts that had been subjected only to ischemia, without the insult of reperfusion, large increases in the mRNAs were not observed, and the protein products were not detected. The fact that the protein products appeared in heart that had been perfused only with oxygenated buffer and was free of serum indicated that heart muscle, and not serum, was the source of the proteins. Furthermore, such ischemia-reperfused hearts expressed higher levels of these proteins than did control rabbit liver.²⁶

In the results of the present study, a contribution from serum to heart complement proteins cannot be ruled out. However, if residual serum were the main source of the complement proteins, comparable levels should have been observed in normal and infarcted areas of the same heart. This was not the case. The levels in infarcted areas were much higher than in normal areas (eg, Figure 4, lane 1 versus lane 2). This is consistent with the previous observations on isolated perfused rabbit hearts, indicating that complement proteins can be locally produced.

C4 mRNA is the most highly expressed of the complement mRNAs in both normal and infarcted heart tissue. C4 is a pivotal component of the classical pathway, because cleavage by activated C1 exposes a thiol ester group on the fragment C4b, through which irreversible, covalent attachment to target tissue takes place. In this case, the target tissue is damaged cardiomyocytes. The attached C4b, complexed with C2a, cleaves C3, exposing a thiol ester group on C3b, which forms another covalent attachment to tissue near C4b2a. Formation of the trimolecular complex C2aC4bC3b completes the opsonization process and also cleaves C5, paving the way for formation of the MAC (C5b-9). The C4b and C3b degrade to form C4d and C3d. Thus, C4d and C3d are excellent markers for activation of the classical complement pathway, because they are amplified products of C1 activation that have become covalently attached to tissue. The presence of C5b-9 demonstrates that full activation of the classical complement pathway has taken place on damaged cardiomyocytes, indicating that these cells are being subjected to cytolytic as well as phagocytic processes. This occurs not only in acutely damaged tissue but also in surviving cardiomyocytes interspersed with collagen in previously infarcted tissue (Figure 6). These results provide evidence that the complement system is exacerbating rather than assisting to resolve the pathological process and that a chronic, autodestructive phenomenon may continue on a long-term basis. Case 5 illustrates that this can extend for at least 3 years after an initial insult.

The immunohistochemical data are in line with previous reports on components specific for complement activation, C4d,⁵ C3d,⁵ and C5b-9^{1 3 4 7} appearing on damaged myocardium after infarction. Activation of the complement system is reported to be initiated within 2 hours of coronary artery obstruction.¹⁴ Large increases in serum levels of the anaphylotoxins C3a and C5a, which are released after full activation of either the classical or alternative pathways, have been observed 16 hours after the onset of an acute myocardial infarction.¹⁷ It therefore appears that complement deposition can appear on cardiomyocytes within a few hours of an insult. Previously, we²⁶ showed that isolated rabbit heart exposed to only 0.5 hours of ischemia followed by 1 hour of reperfusion had a substantial induction of complement mRNAs.

The complement system cannot be activated unless the forces driving activation overcome a multiplicity of endogenous inhibitors. For the classical pathway, these include C1 esterase inhibitor, decay accelerating factor, C4 binding protein, membrane cofactor protein, C8 binding protein, vitronectin, clusterin, and protectin. C1q binding initiates the classical complement cascade. We found C1q mRNA to be the most strongly upregulated (>20-fold) of all the complement mRNAs in infarcted tissue. In general, the upregulation was higher for those genes and proteins normally expressed at lower levels, again consistent with the requirement of overcoming inhibitory factors.

Overall, these data suggest that complement activation exacerbates cardiac damage after infarction and that inhibition of the complement system should contribute significantly to effective treatment. Support for this conclusion comes from numerous studies in animal models in which complement inhibitors have been shown to limit cardiac damage after ischemia. These include C1 esterase inhibitor, CR-1, antibodies to C5a, and heparin-like compounds, which inhibit multiple stages of complement activation.^{18 20 21 22 23 24 25 26 27 28 29 30} Obviously, further investigation of the complement system in human cardiac disease and animal models of ischemic cardiac damage is strongly warranted.

Acknowledgments

This research was supported by a grant from the Jack Brown and Family A.D. Research Fund, as well as donations from individual British Columbians. We would like to thank Dr Eiji Nakagawa and Joane Sunahara for technical assistance and Dr Michael Schulzer, professor of Medicine and Statistics at the University of British Columbia, as well as the biostatistic consultant for Circulation Research, for their invaluable help on the statistical analysis.

Received June 26, 1998; accepted August 20, 1998.

References

1. Hugo F, Handoch T, Mathey D, Schofer HJ, Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132–136.[Medline] [Order article via Infotrieve]

2. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95–105.[Medline] [Order article via Infotrieve]

3. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complex in infarcted areas of human myocardium. J Immunol. 1986;137:1945–1949.[Abstract]

4. Tada T, Okada H, Okada N, Tateyama H, Suzuki H, Takahashi Y, Eimoto T. Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction. Virchows Arch. 1997;430:327–332.[Medline] [Order article via Infotrieve]

5. Lagrand WK, Niessen HWM, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FWA, Meijer CJL, Hack CE. C-Reactive protein colocalized with complement in human hearts during acute myocardial infarction. Circulation. 1997;97:97–103.

6. Schafer H, Mathey D, Bhakdi S. C5b-9 deposition as an immunocytochemical marker for early myocardial infarction and vascular injury. Pathol Res Pract. 1987;182:553. Abstract.

7. Vakeva A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol. 1993;143:65–75.[Abstract]

8. Mathey D, Schofer J, Schafer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J. 1994;15:418–423.[Abstract/Free Full Text]

9. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med. 1971;133:885–900.[Abstract]

10. Beyersdorf F, Allen BS, Buckberg GD, Acar C, Okamoto F, Sjostrand F, Young HH, Bugyi HI. Studies on prolonged acute regional ischemia, I: evidence for preserved cellular viability after 6 hours of coronary occlusion. J Thorac Cardiovasc Surg. 1989;98:112–126.[Abstract]

11. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998;97:795–804.[Abstract/Free Full Text]

12. Pinckard RN, O'Rourke RA, Crawford MH, Grover FS, McManus LM, Ghidoni JJ, Storrs SB, Olson MS. Complement localization and mediation of ischemic injury to baboon myocardium. J Clin Invest. 1980;66:1050–1056.

13. Crawford MH, Grover FL, Kolb WP, McMahan CA, O'Rourke RA, McManus LM, Pinckard RN. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation. 1988;78:1449–1458.[Abstract/Free Full Text]

14. Vakeva A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol. 1994;144:1357–1368.[Abstract]

15. Homeister JW, Lucchesi BR. Complement activation and inhibition in myocardial ischemia and reperfusion. Annu Rev Pharmacol Toxicol. 1994;34:17–40.[Medline] [Order article via Infotrieve]

16. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res. 1992;71:303–319.[Abstract/Free Full Text]

17. Langlois PF, Gawryl MS. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis. 1988;70:95–105.

18. Murahara T, Guo JP, Delyani JA, Lefer AM. Cardioprotective effects of selective inhibition of the two complement activation pathways in myocardial ischemia and reperfusion injury. Methods Find Exp Clin Pharmacol. 1995;17:499–507.[Medline] [Order article via Infotrieve]

19. Vakeva A, Laurila P, Meri S. Co-deposition of clusterin with the complement membrane attack complex in myocardial infarction. Immunology. 1993;80:177–182.[Medline] [Order article via Infotrieve]

20. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393–402.[Abstract/Free Full Text]

21. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P, Becker P, Darius H, Rupprecht HJ, Loos M, Bhakdi S, Meyer J, Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 1997;95:701–708.[Abstract/Free Full Text]

22. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448–H457.[Abstract/Free Full Text]

23. Shandelya SM, Kuppusamy P, Hershowitz A, Weisfeldt ML, Zweier JL. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation. 1993;88:2812–2826.[Abstract/Free Full Text]

24. Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC Jr, Carson GR, Roux KH, Weisfeldt ML, Fearson DT. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians. 1990;103:64–72.[Medline] [Order article via Infotrieve]

25. Ito W, Schafer HJ, Bhakdi S, Klask R, Hansen S, Schaarschmidt S, Schofer J, Hugo F, Hamdoch T, Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc Res. 1996;32:294–305.[Abstract/Free Full Text]

26. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR, McGeer PL. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res. 1998;82:1224–1230.[Abstract/Free Full Text]

27. Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391–395.[Medline] [Order article via Infotrieve]

28. Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer brain. Brain Res. 1997;769:385–390.[Medline] [Order article via Infotrieve]

29. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev. 1995;21:195–218.[Medline] [Order article via Infotrieve]

30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]

31. Haendler B, Hofer-Warbinek R, Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J. 1987;6:947–950.[Medline] [Order article via Infotrieve]

32. Danielson PE, Forss-Petter S, Brow MA, Calavetta L, Douglass J, Milner RJ, Sutcliffe JG. p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. DNA. 1988;7:261–267.[Medline] [Order article via Infotrieve]

33. Innis MA, Gelfand DH. Optimization of PCRs. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols. San Diego, Calif: Academic Press; 1990:3–12.

34. Lowry OH, Rosebrough NJ, Farr AL, Randall EJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275.[Free Full Text]

35. Holm S. A simple sequentially repetitive multiple test procedure. Scand J Stat. 1979;6:65–70.

36. Gomori G. A rapid one-step trichrome stain. Am J Clin Pathol. 1950;20:661–664.[Medline] [Order article via Infotrieve]

37. Frank MM. Complement and kinin. In: Stites DP, Terr AI, eds. Basic and Clinical Immunology. 7th ed. Norwalk, Conn: Appleton & Lange; 1991:161–174.

38. Brachova L, Lue L-F, Schultz J, Rashidy TE, Rogers J. Association cortex, cerebellum and serum concentrations of C1q and factor B in Alzheimer's disease. Mol Brain Res. 1993;18:329–334.[Medline] [Order article via Infotrieve]

39. Wing MG, Seilly DJ, Bridgman DJ, Harrison RA. Rapid isolation and biochemical characterization of rat C1 and C1q. Mol Immunol. 1993;30:433–440.[Medline] [Order article via Infotrieve]

40. Hong Y, Ghebrehiwet B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin Immunol Immunopathol. 1992;62:133–138.[Medline] [Order article via Infotrieve]

41. Davis AE, Harrison RA, Lachmann PJ. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol. 1984;132:1960–1966.[Abstract]

42. Zhou W, Campbell RD, Martin J, Sacks SH. Interferon- regulation of C4 gene expression in cultured human glomerular epithelial cells. Eur J Immunol. 1993;23:2477–2481.[Medline] [Order article via Infotrieve]

43. Maeda S, Takamaru Y, Fukatsu J, Nagasawa S. Identification of a surface structure in the fourth component of human complement, C4, which becomes hidden upon activation by C1s. Biochem J. 1993;289:503–508.

44. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF. Large scale isolation of functionally active components of the human complement system. J Biol Chem. 1981;256:3995–4006.[Abstract/Free Full Text]

45. Nürnberger W. Seger R, Kobler P, Mons I, Tedesco F, Wahn V. Immunoblot analysis of the eighth component of human complement. J Immunol Methods. 1988;109:257–263.[Medline] [Order article via Infotrieve]

46. Biesecker G, Podack ER, Halverson CA, Muller-Eberhard HJ. C5b-9 dimer: isolation from complement lysed cells and ultrastructural identification with complement-dependent membrane lesions. J Exp Med. 1979;149:448–458.[Abstract/Free Full Text]

This article has been cited by other articles:

				Y. Banz, O. M. Hess, S. C. Robson, E. Csizmadia, D. Mettler, P. Meier, A. Haeberli, S. Shaw, R. A. Smith, and R. Rieben Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1 Cardiovasc Res, December 1, 2007; 76(3): 482 - 493. [Abstract] [Full Text] [PDF]

				K. Stasi, D. Nagel, X. Yang, R.-F. Wang, L. Ren, S. M. Podos, T. Mittag, and J. Danias Complement Component 1Q (C1Q) Upregulation in Retina of Murine, Primate, and Human Glaucomatous Eyes. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 1024 - 1029. [Abstract] [Full Text] [PDF]

				D. E. Cramer, D. J. Allendorf, J. T. Baran, R. Hansen, J. Marroquin, B. Li, J. Ratajczak, M. Z. Ratajczak, and J. Yan {beta}-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury Blood, January 15, 2006; 107(2): 835 - 840. [Abstract] [Full Text] [PDF]

				D. A. Lauver, S. F. Lockwood, and B. R. Lucchesi Disodium Disuccinate Astaxanthin (Cardax) Attenuates Complement Activation and Reduces Myocardial Injury following Ischemia/Reperfusion J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 686 - 692. [Abstract] [Full Text] [PDF]

				D. Cadavid, Y. Bai, D. Dail, M. Hurd, K. Narayan, E. Hodzic, S. W. Barthold, and A. R. Pachner Infection and Inflammation in Skeletal Muscle from Nonhuman Primates Infected with Different Genospecies of the Lyme Disease Spirochete Borrelia burgdorferi Infect. Immun., December 1, 2003; 71(12): 7087 - 7098. [Abstract] [Full Text] [PDF]

				T. Vainas, T. Lubbers, F. R.M. Stassen, S. B. Herngreen, M. P. van Dieijen-Visser, C. A. Bruggeman, P. J.E.H.M. Kitslaar, and G. W. H. Schurink Serum C-Reactive Protein Level Is Associated With Abdominal Aortic Aneurysm Size and May Be Produced by Aneurysmal Tissue Circulation, March 4, 2003; 107(8): 1103 - 1105. [Abstract] [Full Text] [PDF]

				M. Kuraya, M. Matsushita, Y. Endo, S. Thiel, and T. Fujita Expression of H-ficolin/Hakata antigen, mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 by human glioma cell line T98G Int. Immunol., January 1, 2003; 15(1): 109 - 117. [Abstract] [Full Text] [PDF]

				T. D. Barrett, J. K. Hennan, R. M. Marks, and B. R. Lucchesi C-Reactive-Protein-Associated Increase in Myocardial Infarct Size After Ischemia/Reperfusion J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1007 - 1013. [Abstract] [Full Text] [PDF]

				P. L. McGeer and E. G. McGeer Innate Immunity, Local Inflammation, and Degenerative Disease Sci. Aging Knowl. Environ., July 24, 2002; 2002(29): re3 - 3. [Abstract] [Full Text] [PDF]

				K. Yasojima, W. W. Tourtellotte, E. G. McGeer, and P. L. McGeer Marked increase in cyclooxygenase-2 in ALS spinal cord: Implications for therapy Neurology, September 25, 2001; 57(6): 952 - 956. [Abstract] [Full Text] [PDF]

				P. Aukrust, L. Gullestad, K. T. Lappegard, T. Ueland, H. Aass, L. Wikeby, S. Simonsen, S. S. Froland, and T. E. Mollnes Complement Activation in Patients With Congestive Heart Failure: Effect of High-Dose Intravenous Immunoglobulin Treatment Circulation, September 25, 2001; 104(13): 1494 - 1500. [Abstract] [Full Text] [PDF]

				K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Complement Components, but Not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1214 - 1219. [Abstract] [Full Text] [PDF]

				C. P. Larsen, R. R. Regal, and J. F. Regal Trimellitic Anhydride-Induced Allergic Response in the Guinea Pig Lung Involves Antibody-Dependent and -Independent Complement System Activation J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 284 - 292. [Abstract] [Full Text]

				E. G. McGeer and P. L. McGeer Innate Immunity in Alzheimer's Disease: A Model for Local Inflammatory Reactions Mol. Interv., April 1, 2001; 1(1): 22 - 29. [Abstract] [Full Text]

				K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques Am. J. Pathol., March 1, 2001; 158(3): 1039 - 1051. [Abstract] [Full Text] [PDF]

				H. Jin, R. Yang, T. A. Awad, F. Wang, W. Li, S.-P. Williams, A. Ogasawara, B. Shimada, P. M. Williams, G. de Feo, et al. Effects of Early Angiotensin-Converting Enzyme Inhibition on Cardiac Gene Expression After Acute Myocardial Infarction Circulation, February 6, 2001; 103(5): 736 - 742. [Abstract] [Full Text] [PDF]

				E. J. Tanhehco, K. Yasojima, P. L. McGeer, E. G. McGeer, and B. R. Lucchesi Preconditioning reduces myocardial complement gene expression in vivo Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H1157 - H1165. [Abstract] [Full Text] [PDF]

				E. J. Tanhehco, K. Yasojima, P. L. McGeer, R. A. Washington, and B. R. Lucchesi Free radicals upregulate complement expression in rabbit isolated heart Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H195 - H201. [Abstract] [Full Text] [PDF]

				P. L. McGeer and E. G. McGeer Autotoxicity and Alzheimer Disease Arch Neurol, June 1, 2000; 57(6): 789 - 790. [Abstract] [Full Text] [PDF]

				E. J. Tanhehco, K. Yasojima, P. L. McGeer, and B. R. Lucchesi Acute Cocaine Exposure Up-Regulates Complement Expression in Rabbit Heart J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 201 - 208. [Abstract] [Full Text]

				E. J. Tanhehco, K. Yasojima, P. L. McGeer, R. A. Washington, K. S. Kilgore, J. W. Homeister, and B. R. Lucchesi Preconditioning reduces tissue complement gene expression in the rabbit isolated heart Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2373 - H2380. [Abstract] [Full Text] [PDF]

				J. L. Park and B. R. Lucchesi Mechanisms of myocardial reperfusion injury Ann. Thorac. Surg., November 1, 1999; 68(5): 1905 - 1912. [Abstract] [Full Text] [PDF]

				Z. Qian, B. A. Wasowska, E. Behrens, D. L. Cangello, J. R. Brody, S. S. Kadkol, L. Horwitz, J. Liu, C. Lowenstein, A. D. Hess, et al. C6 Produced by Macrophages Contributes to Cardiac Allograft Rejection Am. J. Pathol., October 1, 1999; 155(4): 1293 - 1302. [Abstract] [Full Text] [PDF]

				K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Up-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain Am. J. Pathol., March 1, 1999; 154(3): 927 - 936. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yasojima, K. Articles by McGeer, P. L. Search for Related Content PubMed PubMed Citation Articles by Yasojima, K. Articles by McGeer, P. L.